Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26767154 | 1.00 | HTR6 (0.39) | HTR6ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL14395626 | 1.00 | HTR6 (0.39) | HTR6ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL10073208 | 1.00 | HTR6 (0.39) | HTR6ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL597625 | 1.00 | HTR6 (0.39) | HTR6ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL22820393 | 0.94 | HTR6 (0.47) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL12522680 | 0.81 | ADRA1A (0.33) | HTR6ALDH1A1 | |
| SCHEMBL12522594 | 0.81 | ADRA1A (0.33) | HTR6ALDH1A1 | |
| SCHEMBL12350484 | 0.77 | HTR6 (0.36) | HTR6ALDH1A1 | |
| SCHEMBL14856418 | 0.77 | HTR6 (0.36) | HTR6ALDH1A1 | |
| SCHEMBL24306809 | 0.75 | HTR6 (0.39) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022063094-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2010091104-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | EXELIXIS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | HTR6 1155/4885ALDH1A1 50/4885HTR2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.